AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$RVMD

Cislini Jeff sold $159K of RVMD

Cislini Jeff (SVP & General Counsel) sold 765 shares of Revolution Medicines, Inc. (RVMD) at $207.32 ($0.16M total) on 2026-09-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cislini Jeff
Published Sep 29, 2026, 10:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 10:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RVMD
Neutral
medium confidence
Mentioned
$RVMD
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RVMDNeutralLow
01

Why it matters

The filing reveals a modest reduction in insider holdings, which may be interpreted by the market as a neutral or slightly negative signal.

02

Market read

Small insider sale with limited immediate market impact; primarily of interest to existing shareholders.

03

What to watch

Potential upcoming clinical trial results or regulatory updates could amplify the impact of the insider sell.

Relevance 3/10Novelty 3/10Timing: post‑market filing

Background

SEC Form 4 disclosures provide primary source data on insider transactions.

Company-level read

Ticker impact

$RVMDNeutralMedium confidence
Context

Form 4 filing shows SVP & General Counsel Jeff Cislini sold 765 shares for $158.6K via a 10b5‑1 plan.

Expected impact

likely slight downward pressure as market prices in the insider sell.

Evidence & confidence

The sale is modest relative to holdings and typical for a 10b5‑1 plan; no material change to ownership.

Market effects

Sector

Minimal impact on biotech sector; insider sales are routine.

Regional

No regional effect.

Global

Limited to RVMD investors.

Counterpoint

What could challenge this read

The sale could be a signal of upcoming negative news not yet public.

Key entities

  • company
    Revolution Medicines, Inc.

    Biotech firm developing oncology therapies.

  • person
    Jeff Cislini

    SVP & General Counsel, insider seller.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RVMD insider trading history →

Related articles

$RVMDMedAI 8/10

Why is Revolution Medicines stock surging today?

Revolution Medicines (RVMD) stock rose 7% after reporting Q3 revenue of $197.6M, exceeding estimates, driven by its new drug RASONQUE. Analysts raised price targets, with HC Wainwright setting a $350 target. The company has strong cash reserves and reaffirmed its 2026 expense guidance. NASDAQ and S&P 500 gains provided a supportive market backdrop.

investing.com
$RVMDMed

Revolution Medicines Inc (RVMD) Q3 2026 Earnings Call Highlights: RASONQUE's Blockbuster

Revolution Medicines (RVMD) reported $198M in first-month sales for RASONQUE, with inventory levels managed at two weeks. Prescriptions were split 40% academic and 60% community. The company expects payer coverage to evolve, with reimbursement currently strong. RASonate 312 trial is ongoing, and the company is exploring broader colorectal cancer opportunities. Management declined to comment on October trends, citing early launch stage.

finance.yahoo.com
$RVMDHigh

Revolution Medicines (RVMD) Q3 2026 Earnings Call Transcript

Revolution Medicines (RVMD) reported $198M in Q3 2026 revenue from its newly approved drug, RAZONQ, for metastatic pancreatic cancer. The FDA approved the drug in August, and the NCCN guidelines expanded its recommended use. The company is preparing for international expansion and has received positive opinions from the EMA. RAZONQ is also being studied for non-small cell lung cancer.

finance.yahoo.com
$RVMDMed

What Revolution Medicines (RVMD) Said on Its Q3 Earnings Call

Revolution Medicines (RVMD) reported Q3 earnings, highlighting RASONQUE's reimbursement progress, regulatory updates, and pipeline advancements. RASONQUE is included in NCCN guidelines for pancreatic cancer. The company expects European and potential Japanese launches. Q3 revenue included initial stocking, with R&D expenses rising to $417.1M. RVMD ended the quarter with $3.7B in cash. The company reiterated 2026 operating expense guidance and anticipates higher 2027 expenses.

finance.yahoo.com
$RVMDHighAI 9/10

Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

Revolution Medicines, Inc. (RVMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress · Received U.S. FDA approval and launched RASONQUE® (daraxonrasib) for adult patients with metastatic pancreatic cancer who have received at least one prior systemic th

SEC EDGAR 8-K